SGLT2 Inhibitor Reduces CV, Renal Events in Type 2 Diabetes
ADA 2019 —Dapagliflozin reduced CV death, hospitalization for HF, and progression of CKD among T2DM patients with a wide distribution of baselines CVD risk in DECLARE-TIMI 58. (Source: ConsultantLive)
Source: ConsultantLive - June 17, 2019 Category: Internal Medicine Authors: Kenneth Bender, PharmD, MA Tags: Cardiovascular Disease Diabetes Diabetes Type 2 Source Type: news
More DECLARE-TIMI: Robust Renal Effects of Dapagliflozin More DECLARE-TIMI: Robust Renal Effects of Dapagliflozin
A new analysis from the landmark trial with the diabetes drug dapagliflozin shows a large, robust effect on important kidney outcomes. Accumulating data support ' leading role for SGLT2 inhibitors, ' in diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 11, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Qternmet XR (Dapagliflozin, Saxagliptin, and Metformin Hydrochloride) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 8, 2019 Category: Drugs & Pharmacology Source Type: news
Qternmet XR Combinations Approved for Type-2 Diabetes
New drug combines dapagliflozin, saxagliptin, and metformin. (Source: ConsultantLive)
Source: ConsultantLive - May 6, 2019 Category: Internal Medicine Authors: Drew Boxler Tags: Diabetes Diabetes Type 2 Latest e-News New Products The Latest Source Type: news
FDA Approves Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) for Type 2 Diabetes
3 May 2019 -- The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 3, 2019 Category: Drugs & Pharmacology Source Type: news
Dapagliflozin Improves Glucose Outcomes in Type 1 Diabetes
FRIDAY, April 26, 2019 -- In patients with type 1 diabetes, treatment with dapagliflozin for 24 weeks improves time in range, mean glucose, and glycemic variability, according to a study published online April 9 in Diabetes Care.
Chantal Mathieu,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 26, 2019 Category: Pharmaceuticals Source Type: news
Less HF Hospitalization on Dapagliflozin in Diabetes at Any LVEF Less HF Hospitalization on Dapagliflozin in Diabetes at Any LVEF
Survivals gains were seen in DECLARE-TIMI 58 only in those with low ejection fractions. Preliminary, but it suggests an SGLT2 inhibitor benefit in a range of people with diabetes and heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 4, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Forxiga approved in Japan for type-1 diabetes
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D). The approval is based on data from the Phase III DEPICT clinical programme and a dedicated trial in Japanese patients (D1695C00001). (Source: World Pharma News)
Source: World Pharma News - March 27, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
ACC.19: 3 Studies in Cardioprotection
Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA. (Source: ConsultantLive)
Source: ConsultantLive - March 25, 2019 Category: Internal Medicine Authors: Veronica Hackethal, MD Tags: Cardiovascular Disease Source Type: news
EU approves AstraZeneca's drug for adjunct use in Type-1 diabetes
British drugmaker AstraZeneca Plc said on Monday the European Commission approved its diabetes drug Forxiga for use as an oral supplement to insulin in adults with a rare type of the disease. (Source: Reuters: Health)
Source: Reuters: Health - March 25, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Diabetes drug effective against heart failure in wide spectrum of patients
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are especially pronounced in those with reduced ejection fraction, a measure of the heart's pumping ability indicative of poor heart functioning, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. (Source: World Pharma News)
Source: World Pharma News - March 18, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
FDA Approves Expanded Uses for Type 2 Diabetes Drugs FDA Approves Expanded Uses for Type 2 Diabetes Drugs
Dapagliflozin has been okayed for patients with moderate renal impairment, and single-injection GLP-1 agonist/basal insulin combos Soliqua and Xultophy are now approved for earlier intensification of therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Go ahead for first add-on tablet to insulin treatment for type 1 diabetes
European regulator recommends dapagliflozin for those with poor blood glucose control despite best efforts Related items fromOnMedica Use of DPP-4 inhibitors associated with increased risk of IBD Adding insulin to metformin linked to higher mortality Draft diabetes guidance too heavily focused on cost, protests industry MHRA tightens licence restrictions on valproate for women Withdrawn valsartan meds not linked to short-term cancer risk (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 5, 2019 Category: UK Health Source Type: news
Forxiga receives positive EU CHMP opinion for the treatment of adults with type-1 diabetes
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxiga (dapagliflozin), after adopting a positive opinion for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D). (Source: World Pharma News)
Source: World Pharma News - February 4, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
EU Panel Backs Dapagliflozin for Some With Type 1 Diabetes EU Panel Backs Dapagliflozin for Some With Type 1 Diabetes
If approved, it would be the first oral add-on to insulin worldwide, but could only be used in patients in whom risk of diabetic ketoacidosis can be properly mitigated.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
